Isis Pharmaceuticals News

Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced that it has secured $17 million in a subsequent financing round.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 11/05/09, Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals Inc. filed Quarterly Report for the period ended 2009-09-30. Isis Pharmaceuticals Inc.

Drug stocks gained Thursday, but shares of Alnylam Pharmaceuticals fell a day after the company reported a widened third-quarter loss and said its search for research partners is taking longer than expected.

Xconomy.com -- Isis Pharmaceuticals likes to talk about how its gene-silencing technology known as antisense creates so many innovative ideas for new drugs that it cana t commercialize them all itself, so it spins a few off into what CEO Stanley Crooke calls a oesatellite companies.a One of the more interesting ideas orbiting around Isis in ...

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. , and Isis Pharmaceuticals, Inc.

OUR TOP TWO IDEAS in the biotech sector remain Amgen and Isis Pharmaceuticals ; recent weakness, strong earnings from Amgen, and positive clinical data from Isis strengthen our enthusiasm for these stocks.

Earlier this week, Isis Pharmaceuticals, Inc. reported positive top-line results on its type II diabetes candidate, ISIS-113715. Results from the phase II study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control.

Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes.

I highlighted Isis Pharmaceuticals a few weeks ago believing that a sell-off causing a price decline from $19 to $16/share was a prime opportunity to buy a potential high-growth business.

FOLLOWING RECENT profit-taking, we are adding Onyx Pharmaceuticals to our biotechnology trading list.

Regulus Therapeutics Inc., Alnylam Pharmaceuticals, Inc. , and Isis Pharmaceuticals, Inc.

The Danish biotechnology company Santaris Pharma has established a San Diego operation and hired former Isis Pharmaceuticals vice president Arthur A. Levin to head it.

Santaris Pharma , the Danish company that has pushed the first microRNA therapy into clinical trials , is opening a U.S. subsidiary in San Diego to take advantage of the talent pool of people familiar with cutting-edge RNA-based therapies.

Our analysts have issued free ratings reports on the following six companies: Biogen Idec Inc.

Isis Pharmaceuticals, Inc. , the leader in antisense therapeutics, today announced that management will present a company overview at the 2009 Thomas Weisel Partners Healthcare Conference on Wednesday, September 9, 2009, at 11:30 a.m. ET at the Boston Four Seasons Hotel.

I recently highlighted a small biotech firm, ISIS Pharmaceuticals, as a potential "value" growth play .

TAKING, we are adding ImmunoGen and Isis Pharmaceuticals to our short-term trading list.

Sadly, there's no such thing as an ultimate buy signal when it comes to investing in stocks.

OncoGenex Pharmaceuticals, Inc. announced today it has entered into purchase agreements with certain institutional investors for the sale of 475,000 shares of its common stock at a price of $20 per share through a registered direct offering.